Pan-KRAS-IN-6 is a small molecule inhibitor designed to target KRAS mutations, particularly those associated with various cancers. It is part of a class of compounds aimed at disrupting the oncogenic signaling pathways activated by mutant KRAS proteins. The substance is characterized by its ability to selectively inhibit the activity of KRAS, thereby impeding tumor growth and proliferation. Its mechanism of action typically involves binding to the mutant form of KRAS, preventing downstream signaling that contributes to cancer cell survival and proliferation. Pan-KRAS-IN-6 is often evaluated in preclinical and clinical studies for its efficacy and safety in treating KRAS-driven malignancies. As with many targeted therapies, its development is accompanied by a focus on understanding resistance mechanisms and optimizing treatment regimens. The compound's pharmacokinetics, bioavailability, and potential side effects are also critical areas of investigation to ensure effective therapeutic outcomes in patients with KRAS mutations.

pan-KRAS-IN-6

3033565-36-2: Pan-KRAS-IN-6 is a small molecule inhibitor designed to target KRAS mutations, particularly those associated with various cancers. It is part of a class of compounds aimed at disrupting the oncogenic signaling pathways activated by mutant KRAS proteins. The substance is characterized by its ability to selectively inhibit the activity of KRAS, thereby impeding tumor growth and proliferation. Its mechanism of action typically involves binding to the mutant form of KRAS, preventing downstream signaling that contributes to cancer cell survival and proliferation. Pan-KRAS-IN-6 is often evaluated in preclinical and clinical studies for its efficacy and safety in treating KRAS-driven malignancies. As with many targeted therapies, its development is accompanied by a focus on understanding resistance mechanisms and optimizing treatment regimens. The compound's pharmacokinetics, bioavailability, and potential side effects are also critical areas of investigation to ensure effective therapeutic outcomes in patients with KRAS mutations.

<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>

CAS 3033565-36-2

pan-KRAS-IN-6

pan-KRAS-IN-6

Ref: TM-T88001